Copyright © 2011-2016 Ascletis Inc. All rights reserved.


News & Events

Investor Center




About  Us

About Us

Research & Development

Research & Development Pipeline Partership Investor Center News & Events Careers
Contact    Home    Home-Ch

Corporate Overview

Management Team

Board of Directors


Management Team Board of Directors Founders About Us

While Ascletis is conducting in-house drug discovery and development, our entrepreneurial spirit and commitment to bringing breakthrough therapeutics to patients drive us to explore business opportunities beyond our own internal effort.  At Ascletis, we search globally for innovative product candidates at various stages of development, with a clear goal to accelerate the delivery of novel and effective products to the China marketplace as well as markets worldwide.

Ascletis understands that the path from scientific breakthrough to successful therapeutic products depends on successfully utilizing the best global resources, expertise and experience. Ascletis is dedicated to bringing considerable resources and expertise to its alliances, and open to different collaboration structures.

We look forward to the opportunity to work with you. If you would like more information on partnering with Ascletis, please contact our business development team via e-mail at

July 12, 2012/ Ascletis and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that they have formed a strategic collaboration for the development of ALN-VSP, a first-in-class, systemically delivered RNAi therapeutic for the treatment of liver cancers including hepatocellular carcinoma (HCC)--a significant area of unmet need in ChinaAsia.  This collaboration provides Ascletis with the exclusive rights to develop and commercialize ALN-VSP in China, as well as Hong Kong, Macau, and and Taiwan.  Alnylam will retain all rights in the rest of the world, and is eligible to receive milestones and royalties based on product sales. Learn More About Alnylam >>

April 15, 2013 / Roche and Ascletis announced today that they have entered into a collaboration to develop and commercialize Roche's investigational drug danoprevir in China for the treatment of Hepatitis-C Virus (HCV). Under the terms of the agreement, Ascletis will fund and be responsible for the development, regulatory affairs and manufacturing of danoprevir in greater China, including Taiwan, Hong Kong and Macau and receive payments upon reaching certain development and commercial milestones from Roche. Ascletis and Roche will collaborate for the clinical development and the commercialization.

Learn More About Roche >>

April 30, 2013 / Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in Greater China, including mainland China and Macau. This is third product in growing Ascletis pipeline of infectious desease and cancer therapeutica. Learn More About Janssen >>

Nov 10, 2014 / Ascletis and Presidio announced today that they have entered into an exclusive licensing agreement for Presidio’s clinical stage, HCV NS5A inhibitor PPI-668, also known as ASC16. The agreement provides Ascletis with exclusive rights to develop and commercialize PPI-668 in Greater China.  Presidio will retain all rights in the rest of the world. Learn More About Presidio >>